久久久综合精品一区二区三区,色综合久久中文字幕无码,国产成人av一区二区三区不卡,少妇愉情理伦片高潮日本

On March 27, 2021, the Commendation and Oath-taking Conference of COVID-19 vaccine project partners was held under the theme of “Fight as One to Safeguard Life” at SINOPHARM CNBG Beijing Institute of Biological Products Co., Ltd.. Truking Technology Limited was granted with the “Outstanding Contribution Team Award” by SINOPHARM as the recognition of its outstanding contribution towards the mass production of COVID-19 vaccine. Mr. Zeng Fanyun, CEO of Truking Technology Limited was invited to attend the conference. He accepted the award and delivered a speech on behalf of the company.

Mr. Liu Jingzhen, Chairman of SINOPHARM, attended the conference and remarked that, the COVID epidemic has never been gone, and human health is still under threat. Therefore, there is still enormous pressure cast upon the vaccine production. We shall once again break the record to expand the production capacity rapidly to meet the demands of both the Chinese and the whole body of mankind.

Mr. Wang Hui, Chief Director of Beijing Institute of Biological Products Co., Ltd., announced at the conference that, SINOPHARM has offered over 100 million doses of COVID vaccine globally. Although the epidemic has been put under control in China, the international pandemic is not optimistic. We have to establish our phase III workshop with the fastest speed to contribute in our Chinese way to the accessibility and affordability of COVID vaccines in the developing countries.

Then, Mr. Liu Jingzhen, Chairman of SINOPHARM, launched the countdown of “100-day Combat” for the construction of Phase III workshop for the COVID vaccine production of SINOPHARM CNBG Beijing Institute of Biological Products Co., Ltd.. SINOPHARM shall make every effort to accomplish the mission as a tribute to the 100 anniversary of the establishment of the Party. SINOPHARM shall also take the initiative to make its due contributions to the human community of hygiene and health.

By Feb. 15, 2020, SINOPHARM CNBG Beijing Institute of Biological Products Co., Ltd. successfully established the 1st brand new high level biosafety production workshop of COVID vaccine in the world in 58 days, with the joint efforts of all partners, creating a “HUOSHENSHAN Hospital” record of COVID vaccine workshop construction.

Mr. Yang Huichuan, VP of CNBG, presented the “Outstanding Contribution Team Award” to Mr. Zeng Fanyun, CEO of Truking Technology Limited.

Truking equipment has managed to secure the stable production with its excellent operation performance, which are highly appreciated by SINOPHARM. The star equipment here is compact line for washing, filling and sealing, smart detection equipment, secondary packaging line, and to name just a few. Truking has taken a leading position in equipment supply for COVID vaccine primary and secondary packaging. Its contribution therefore in the mass production and capacity expansion of COVID vaccine is highly recognized.

Being the important partner of SINOPHARM CNBG Beijing Institute of Biological Products Co., Ltd. to advance the mass production of COVID vaccine, Truking assigned nearly 100 engineers to work overtime at Beijing Institute of Biological Products Co., Ltd. during the 2021 Spring Festival holiday. Truking entered the “wartime mechanism” to work with “wartime speed”. Chairman of the BOD and President of Truking, Mr. Tang Yue personally visited Beijing Institute of Biological Products Co., Ltd. to the engineers and encouraged them to step up and accomplish the mission.

Mr. Zeng Fanyun, CEO of Truking Technology Limited, stated that SINOPHARM CNBG took the lead in developing the safe, reliable and effective COVID vaccine. It’s the best demonstration of “made-in-China, speed-of-China, and Quality-of China”. Truking is a private enterprise with patriotism. We would stay with our original while continue to explore and innovate for better technology, better production and better service, through a realistic and pragmatic approach. Truking would also open for international cooperation under the concept of common future, to equip the bio industry with intelligent wings, and to make more significant contribution to the biopharma industry.